STAT-200

STAT-200 is a proprietary **noroxymorphone analog** program from **Statera Biopharma** within the company's **Advanced Immunomodulating Multi-component System** platform. Available company materials describe STAT-200 compositions as originally designed to antagonize opioid receptors, but later found to exert broader **immunomodulatory** activity by modulating the **opioid growth factor and opioid growth factor receptor axis**, **Toll-like receptors**, and downstream intracellular signaling pathways that regulate inflammatory cytokines, cell proliferation, and multiple cellular compartments. The program has been positioned as a late-stage developmental platform with potential applications across **cancer**, **inflammatory diseases**, **autoimmune diseases**, and **emerging viral infections**, with specific public mentions including **Crohn's disease** and **COVID-19**. Because public disclosures describe STAT-200 mainly as a platform-derived family of compositions rather than a single fully defined molecular entity, its exact clinical composition, dosage form, and route have not been clearly specified.

Other names

STAT-200 AIMS programSTAT200 AIMS programSTAT 200 AIMS program